MiMARK Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 28

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Latest Deal Amount
  • $9.2M

  • Investors
  • 15

MiMARK General Information

Description

Operator of a biotech platform designed to reshape gynecological diagnostics through fluid-based testing. The company's platform utilizes gynecological fluid analysis as an approach to liquid biopsy, developing immunoassay-based diagnostics for conditions such as endometrial cancer, biomarker quantification for accuracy, reducing invasiveness, and supporting clinical decision-making, enabling healthcare providers to improve early detection, optimize patient outcomes, and women's health through innovative screening methods.

Contact Information

Website
www.mimark.es
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avinguda Dr. Gregorio Marañón, num. 8
  • Parc Científic de Barcelona, Clúster 2, CL02D81
  • 08028 Barcelona
  • Spain
Primary Industry
Other Devices and Supplies
Other Industries
Diagnostic Equipment
Biotechnology
Vertical(s)
FemTech, Oncology
Corporate Office
  • Avinguda Dr. Gregorio Marañón, num. 8
  • Parc Científic de Barcelona, Clúster 2, CL02D81
  • 08028 Barcelona
  • Spain

MiMARK Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MiMARK Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series A) 11-Aug-2026 $9.2M In Progress Product Development
13. Debt - General Completed Product Development
12. Later Stage VC 01-Oct-2025 Completed Product Development
11. Accelerator/Incubator Completed Product Development
10. Debt - General 01-Dec-2023 Completed Product Development
9. Grant 01-Oct-2023 Completed Startup
8. Seed Round 01-Oct-2023 Completed Startup
7. Grant 01-Jan-2023 Completed Startup
6. Accelerator/Incubator 01-Jan-2023 Completed Startup
5. Accelerator/Incubator 01-Jan-2023 Completed Startup
To view MiMARK’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

MiMARK Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech platform designed to reshape gynecological diagnostics through fluid-based testing. The company's
Other Devices and Supplies
Barcelona, Spain
28 As of 2026

Innsbruck, Austria

Sunderland, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MiMARK Competitors (3)

One of MiMARK’s 3 competitors is Sola Diagnostics, a Venture Capital-Backed company based in Innsbruck, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sola Diagnostics Venture Capital-Backed Innsbruck, Austria
Arquer Diagnostics Formerly VC-backed Sunderland, United Kingdom
cisploy Corporation
You’re viewing 3 of 3 competitors. Get the full list »

MiMARK Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • Pending

  • Expiring in next 12 mo

MiMARK Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12510542-B1 Capture antibody and detection antibody binding mmp9 protein Active 18-Jun-2025

MiMARK Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MiMARK Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Institut Català de Finances Venture Capital Minority
Canterbury Scientific Corporation Minority
CDTI Innvierte Government Minority
Clave (Pamplona) Venture Capital Minority
European Innovation Council Accelerator/Incubator Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

MiMARK FAQs

  • When was MiMARK founded?

    MiMARK was founded in 2021.

  • Where is MiMARK headquartered?

    MiMARK is headquartered in Barcelona, Spain.

  • What is the size of MiMARK?

    MiMARK has 28 total employees.

  • What industry is MiMARK in?

    MiMARK’s primary industry is Other Devices and Supplies.

  • Is MiMARK a private or public company?

    MiMARK is a Private company.

  • What is MiMARK’s current revenue?

    The current revenue for MiMARK is .

  • How much funding has MiMARK raised over time?

    MiMARK has raised $4.06M.

  • Who are MiMARK’s investors?

    Institut Català de Finances, Canterbury Scientific, CDTI Innvierte, Clave (Pamplona), and European Innovation Council are 5 of 15 investors who have invested in MiMARK.

  • Who are MiMARK’s competitors?

    Sola Diagnostics, Arquer Diagnostics, and cisploy are competitors of MiMARK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process